ArticleOphthalmology and therapy2018
Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study.
Article in Ophthalmology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The public health impact of making chloramphenicol an over-the-counter antibiotic: a systematic literature review.International ophthalmology · 2025Pooled it
- Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.Antimicrobial resistance and infection control · 2019Pooled it
- In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.The Journal of antimicrobial chemotherapy · 2026Article
- Management of neurotrophic corneal ulcer with a topical liposomal ozonated oil: A report on three clinical cases.American journal of ophthalmology case reports · 2025Article
- Rapid diagnostic value of next-generation sequencing-based technologies in childhood pneumonia.Frontiers in pediatrics · 2025Article
- Microbiology and management of Staphylococcus aureus lacrimal system infections: A 10-year retrospective study.PloS one · 2024Article
- Antimicrobial Susceptibility Profiles ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States.Ophthalmology and therapy · 2022Review
- Prevalence and Antimicrobial Resistance of Causative Agents to Ocular Infections.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- The Incidence and Outcomes of Recurrence of Infection after Therapeutic Penetrating Keratoplasty for Medically-Uncontrolled Infectious Keratitis.Journal of clinical medicine · 2020Article
- Northeastern U.S. Salmonella Strains from Retail Meat Are More Prevalent and More Resistant to Antimicrobials.Journal of food protection · 2020Article
- Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.JAMA ophthalmology · 2020Article
- Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration.Ophthalmology and therapy · 2019Article
- Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.Microorganisms · 2019Review
- Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin AgainstFrontiers in microbiology · 2019Article
- Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).Clinical optometry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) study is an ongoing nationwide surveillance program that surveys in vitro antibiotic resistance rates and trends among ocular bacterial pathogens. We report resistance rates by geographic region for isolates collected from 2009 through 2016.
methodsStaphylococcus aureus, coagulase-negative staphylococci (CoNS), Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa isolates from ocular infections were collected at clinical centers across the US and categorized by geographic region based on state. Minimum inhibitory concentrations (MICs) for various antibiotics were determined at a central laboratory, and isolates were classified as susceptible or resistant based on established breakpoints. Geographic differences in methicillin resistance among staphylococci were evaluated by χ
resultsOverall, 4829 isolates (Midwest, 1886; West, 1167; Northeast, 1143; South, 633) were evaluated. Across all regions, azithromycin resistance was high among S. aureus (49.4-67.8%), CoNS (61.0-62.8%), and S. pneumoniae (22.3-48.7%), whereas fluoroquinolone resistance ranged from 26.1% to 47.8% among S. aureus and CoNS. Across all regions, all staphylococci were susceptible to vancomycin; besifloxacin MICs were similar to those of vancomycin. Geographic differences were observed for overall mean resistance among S. aureus, S. pneumoniae, and P. aeruginosa isolates (p ≤ 0.005); no regional differences were found among CoNS and H. influenzae isolates. Methicillin resistance in particular was higher among S. aureus isolates from the South and CoNS isolates from the Midwest (p ≤ 0.006).
conclusionThis analysis of bacterial isolates from the ARMOR study demonstrated geographic variation in resistance rates among ocular isolates, with greater in vitro resistance apparent in the South and Midwest for some organisms. These data may inform clinicians in selecting appropriate treatment options for ocular infections.
fundingBausch & Lomb, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.